Sharp Investments Proposes Preferential Issue Through Share Swap
“Sharp Investments announced a proposed preferential issue of equity shares for an acquisition via a share swap.”
Sharp Investments Plans Preferential Issue
Sharp Investments Limited has proposed to issue up to 27,51,51,600 equity shares on a preferential basis. The proposed shares will be issued at rupee 1 per share and will be allotted only to non-promoter entities.
The issue is being structured as consideration other than cash, with the proposed allotment linked to the acquisition of shares in Rajal Lefin & Commercial Private Limited.
Issue Details
- Maximum Shares Proposed: 27,51,51,600 equity shares
- Issue Price: rupee 1 per share
- Nature of Issue: Preferential allotment
- Category of Allottees: Non-promoter entities
- Consideration: Other than cash through a share swap
What to Watch Next
Investors may track the shareholders' approval, completion of the preferential allotment, acquisition of the RLCPL stake and the company's post-issue shareholding structure.
Disclaimer
Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)
Other News
IRB Infrastructure Developers Completed 2,351cr Capital Through its Sponsored IRB InvIT Fund.
IRB Infrastructure Developers has announced the successful completion of a Rs.2,351 crore fundraise by its sponsored IRB InvIT Fund through a Qualified Institutional Placement (QIP) and preferential allotment of units.
Lupin Gets U.S. FDA Tentative Approval for Apixaban Oral Suspension
Lupin Limited has received tentative approval from the U.S. FDA for its Apixaban Oral Suspension 1.25 mg/mL, an oral liquid formulation of apixaban intended for patients requiring anticoagulation treatment.
Kalpataru Projects Wins Major UAE Gas Pipeline EPC Order
Kalpataru Projects International Limited (KPIL) has secured a major Engineering, Procurement and Construction (EPC) order for a gas pipeline project in the United Arab Emirates (UAE). The company received a Letter of Award (LoA) for the EPC contract, with the order classified as 'Major' and estimated to be valued at over Rs.4,000 crore. KPIL said the order reinforces its capabilities and track record in the global Oil and Gas sector.